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ACUTE EXACERBATION OF CHRONIC BRONCHITIS (AECB)
TREATMENT EFFECTIVENESS: COMPARISON OF
MACROLIDES TO FLUOROQUINOLONES
Wu EQ1, Birnbaum H1, Cifaldi M2, Kang YJ1, Colice GL3
1Analysis Group, Inc, Boston, MA, USA; 2Abbott Laboratories,
Abbott Park, IL, USA; 3Washington Hospital Center, Washington, DC,
USA
OBJECTIVES: The purpose of this study is to compare the 
effectiveness of ﬂuoroquinolones versus macrolides in treating
AECB. METHODS: The study sample was identiﬁed from a
large employer claims database covering the period 1999–2002.
Patients age 18–65 years with at least one diagnosis of AECB
were included in the study sample. The sample was further
restricted to AECB patients who had 13 months pre-index date
continuous eligibility. The index date was deﬁned as the date of
the ﬁrst prescription of either a macrolide or a ﬂuoroquinolone
during the period between 14 days before an AECB diagnosis
and 30 days following the diagnosis. The effectiveness, measured
by treatment failure rate, of ﬂuoroquinolones and macrolides,
were compared using multivariate logistic regression adjusting
for gender age, season of the year, additional oxygen therapy,
and patient COPD severity as measured by a severity score
developed by Wu, et al. Treatment failure rate was deﬁned as
occurrence of hospitalization, ER visit, switching of antibiotics,
ﬁlling of a second prescription of antibiotic, or use of oral cor-
ticosteroids within one-month following the index date, and was
compared using odds ratio (OR). Patients were categorized into
severe COPD (top 25% of severity distribution) and non-severe
(moderate/mild) COPD patients. RESULTS: When treated with
macrolides, severe COPD patients had signiﬁcantly lower failure
rates compared with patients on ﬂuoroquinolones (OR = 2.01,
p = 0.03). There are no differences in failure rate between
macrolides and ﬂuoroquinolones in treating moderate and mild
COPD patients. CONCLUSIONS: Macrolides are more effective
ﬁrst line therapies compared to ﬂuoroquinolones when treating
ﬂare-ups of severe COPD patients.
PRS4
ESTIMATING THE NUMBER OF CASES OF DIAGNOSED
CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD):
USE OF MEDICAL CLAIMS DATA VERSUS ALTERNATIVE
METHODOLOGIES
Miller JD1, Boulanger L1, Russell MW1, Marton J2, Menzin J1
1Boston Health Economics, Inc, Waltham, MA, USA; 2Pﬁzer Inc, New
York, NY, USA
OBJECTIVES: To estimate the prevalence and annual incidence
of diagnosed COPD from medical claims data and to compare
results with those derived through alternative methodologies.
METHODS: Claims data were acquired from a US managed 
care organization database with records for approximately ten
million members in 20 states. The COPD cohort comprised
patients aged 25+ years with one or more medical claims with a
COPD diagnosis in 2002. For prevalence, patients were required
to be eligible for coverage during 2002, while patients in the inci-
dence estimation were required to be eligible for medical cover-
age in both 2001 and 2002 but without any COPD diagnoses 
in 2001. Claims-based estimates of prevalence and incidence
(overall and by age group) were compared to corresponding pub-
lished data from other sources. RESULTS: We identiﬁed 64,141
patients with a diagnosis of COPD (an overall prevalence of
3.7%). Prevalence progressively increased from 0.3% in patients
aged 25–34 years to 11.8% in patients aged 75+ years. These
estimates are generally lower than other sources. For example,
National Health Interview Survey estimates, based on respon-
dent self-reported COPD or recall of being told they have the
disease, ranged from 3.9% to 10.6% in the youngest and oldest
age groups, and were about 6.0% overall. A total of 7347 newly-
diagnosed COPD patients were found, generating an annual inci-
dence rate of 0.95%. Rates increased from 0.08% in patients
aged 25–34 years to 2.07% in patients aged 75+ years, some-
what higher than estimates from European studies that used
general practitioner case registrations as a data source. No com-
parable U.S. studies could be identiﬁed. CONCLUSION: Dis-
parities exist in epidemiological estimates of COPD depending
on data, patient populations, and methodologies employed.
Further studies are needed to clarify the most valid and reliable
data and methods for studying the epidemiology of diagnosed
COPD.
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OBJECTIVE: COPD is a progressive and debilitating disease.
The purpose of this study was to directly characterize utility and
hospital resource use in people with COPD. METHODS: Data
were abstracted from the Health Outcomes Data Repository
(HODaR) describing the treatment patterns and outcomes of
299 subjects with COPD with corresponding lung function 
measurements. Patients were classiﬁed according to the GOLD
classiﬁcation based on their actual to predicted FEV1values. Pre-
dicted FEV1values were estimated from a subjects’ height, age
and sex. These patients were hospital treated subjects. Total
mean number of visits to/from a GP and practice nurse were cal-
culated in the six weeks prior to the survey, along with a measure
of utility (EQ5Dindex). RESULTS: Of the 299 subjects, there were
11 (3.7%), 74 (24.7%), 140 (46.8%) and 74 (24.7%) in GOLD
classes I to IV, respectively. There was an inverse association
between the GOLD classiﬁcation and mean EQ5Dindex: 0.52
(0.27), 0.44 (0.34), 0.42 (0.33) and 0.39 (0.31), for GOLD
classes I to IV, respectively. Regarding resource use, in the year
prior to their most recent FEV1 measurement was on average 2.1,
2.3, 2.4 and 2.1 hospital admissions for GOLD I to IV, respec-
tively. Additionally, the mean length of stay in the previous year
was 11.6, 16.6, 17.7 and 17.3 days, correspondingly. Mean (SD)
primary care visits increased from 2.9 (2.5) per person for
GOLD-I to 4.6 (7.4) for GOLD-IV, respectively. CONCLU-
SIONS: The EQ5Dindex estimates showed clearly that this disease
results in very poor quality of life, and that this is inversely asso-
ciated with disease severity. COPD was also extremely resource
intensive in all stages of disease severity. The changes in the lungs
of patients with COPD are irreversible; however, active chronic
disease management strategies may impact on the ﬁnancial and
humanistic cost of this disease.
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COMPARISON OF RESOURCE USE AND DIRECT COSTS OF
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WITHOUT COMORBID DEPRESSION IN 2001
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OBJECTIVES: The objectives of this study were to determine
and compare resource utilization and direct costs for adults diag-
nosed with chronic obstructive pulmonary disease with and
